Shell (via Shell Overseas Investment B.V.) is to acquire sonnen, a German provider of smart energy storage systems and innovative energy services for households.
Calypso Biotech, an Amsterdam, the Netherlands-based developer of therapeutic antibodies for autoimmune diseases, closed a €20M Series A financing.
Sapreme Technologies, an Utrecht, the Netherlands-based biotech company developing a technology platform to enable the cytosolic delivery of macromolecule therapeutics, has been awarded a 6.8 M€ grant together with a multidisciplinary consortium including 11 other academic and industrial parties.
Utrecht, The Netherlands-based Rabobank’s strategic investment arm Rabo Frontier Ventures has secured €80M for a new round of investments in FinTech and AgTech companies.
E&A Scheer, a global blender and vendor of premium rum in bulk, reveived a significant investment from global private equity firm The Riverside Company.
Bright River, a Haarlem, the Netherlands-based provider of visual content solutions for e-commerce brands, received an investment from Pride Capital Partners.
Nordsol, a Bunnik, Netherlands-based BioLNG production and technology company, received a minority investment from Shell Ventures.
Your Super, a line of natural, organic, plant-based superfood mixes made exclusively of whole food ingredients, raised $5m in Series A funding.
GeoPhy, a Delft, The Netherlands-based, powered real estate valuation platform, secured $33m in Series B funding.
Polarsteps, an Amsterdam, The Netherlands-based travel startup, raised €3m in Series A funding.
Cafedeco, an Amsterdam, The Netherlands-based online interior platform, raised €300k in funding.
ScanMovers, an Amsterdam, The Netherlands-based moving platform, raised €750k in funding.
dott, an Amsterdam, The Netherlands–based micro-mobility company, raised €20m in funding.
Inkef Capital, an Amsterdam, The Netherlands-based venture capital fund focused on technology and healthcare, has appointed Roel Bulthuis as Managing Director and Head of Healthcare Team.
Forbion, a European life science venture capital firm, will add Carlo Incerti, M.D., as Operating Partner, effective 1 January 2019.